Skip to main content

Table 3 The baseline characteristics in subjects according to the combination of habitual exercise (performance/non-performance) and hyperglycemia (presence/absence)

From: The joint impact of habitual exercise and glycemic control on the incidence of chronic kidney disease (CKD) in middle-aged and older males

  Performance of habitual exercise Non-performance of habitual exercise p for ANOVA
NGT (n = 122) Hyperglycemia (n = 26) NGT (n = 133) Hyperglycemia (n = 22)
eGFR (ml/min/1.73 m2) 77.2 ± 10.7 78.6 ± 10.8 76.9 ± 10.4 73.9 ± 7.2 0.443
Classifications of CKD grade
 G1 (n, %; eGFR ≥ 90 ml/min/1.73 m2) 10 (8.2) 3 (11.5) 16 (12.0) 0 (0) 0.247
 G2 (n, %; eGFR 60–89 ml/min/1.73 m2) 112 (91.8) 23 (88.5) 117 (88.0) 22 (100)  
Serum creatinine (mg/dl) 0.84 ± 0.10 0.81 ± 0.10 0.85 ± 0.09 0.85 ± 0.08 0.363
Age (years) 50.5 ± 6.8 54.8 ± 6.4 52.6 ± 6.5 56.0 ± 5.3 a 0.002
Body weight (kg) 67.4 ± 9.8 69.3 ± 10.4 67.0 ± 8.5 69.4 ± 10.1 0.515
BMI (kg/m2) 23.0 ± 2.4 23.7 ± 2.2 23.3 ± 2.9 23.4 ± 2.4 0.937
Waist circumference (cm) 83.2 ± 8.2 84.3 ± 7.1 83.3 ± 6.8 85.5 ± 9.1 0.566
SBP (mmHg) 123.6 ± 15.1 132.7 ± 13.0 127.4 ± 14.1 134.5 ± 20.5 a 0.001
DBP (mmHg) 82.3 ± 10.2 85.6 ± 12.4 82.8 ± 10.2 85.4 ± 10.5 0.341
LDL-C (mg/dl) 117.3 ± 26.2 117.7 ± 25.3 120.7 ± 24.3 114.6 ± 24.0 0.486
HDL-C (mg/dl) 60.7 ± 12.8 56.8 ± 13.0 55.8 ± 14.8 54.3 ± 14.3 a 0.032
Triglyceride (mg/dl) 109.2 ± 67.7 111.1 ± 68.0 139.4 ± 76.3 141.8 ± 77.4 0.052
Fasting glucose (mg/dl) 94.1 ± 9.8 126.5 ± 26.4 a, b 96.6 ± 7.4 129.3 ± 28.6 a, b < 0.0001
HbA1c (NGSP values; %) 5.5 ± 0.4 6.3 ± 1.3 a, b 5.5 ± 0.4 6.4 ± 0.9 a, b < 0.0001
HbA1c (IFCC values; %) 36.2 ± 3.8 46.3 ± 14.8 a, b 36.6 ± 4.4 46.8 ± 10.2 a, b < 0.0001
Smoking habit (yes/no; n, %) 27 (22.1)/95 (77.9) 3 (11.5)/23 (88.5) 29 (21.8)/104 (78.2) 4 (18.2)/18 (81.8) 0.630
Drinking habit (yes/no; n, %) 100 (82.0)/22 (18.0) 19 (73.1)/7 (26.9) 96 (72.2)/37 (27.8) 17 (77.3)/5 (22.7) 0.102
Anti-hypertensive drugs (yes/no; n, %) 16 (13.1)/106 (86.9) 3 (11.5)/23 (88.5) 15 (11.3)/118 (88.7) 9 (40.9)/13 (59.1) 0.003
Anti-hyperlipidemic agents (yes/no; n, %) 14 (11.5)/108 (88.5) 3 (11.5)/23 (88.5) 5 (3.8)/128 (96.2) 3 (13.6)/19 (86.4) 0.127
Hypoglycemic drugs (yes/no; n, %) 0 (0)/122 (100) 2 (7.7)/24 (92.3) 0 (0)/133 (100) 5 (22.7)/17 (77.3) < 0.0001
  1. The data are expressed as the mean ± standard deviation and the number of subjects
  2. The abbreviations are the same as those in Table 1
  3. a p < 0.05, compared to the NGT subjects who performed habitual exercise
  4. b p < 0.05, compared to the NGT subjects who did not perform habitual exercise